On the evening of June 15, the Intensive Care Center located at Bac Giang Psychiatric Hospital intervened ECMO (artificial cardiopulmonary bypass) for 2 severe COVID-19 patients.
The first patient is female, HTH, 37 years old, admitted to Bac Giang Lung Hospital on May 26. The patient was given oxygen but the disease progression was not good.
On May 28, the patient was given high-flow oxygen (HFNC). On June 2, the patient was intubated with mechanical ventilation, osiris dialysis, and used antibiotics. At 8pm on June 14, the patient was transferred to the Intensive Care Center (ICU, 101 beds, the largest in the North) and continued to receive mechanical ventilation, dialysis, and vasopressors. However, the patient’s condition developed very severe heart failure, had to take high-dose vasopressors, had bilateral diffuse lung damage, and did not respond to optimal medical treatment. At 4 pm on 15/6, the patient was assigned to place ECMO. Experts from the Intensive Care Center in Bac Giang are still making efforts to treat patients with COVID-19. According to Dr. Nguyen Tan Hung, deputy head of the Department of Intensive Care and Anti-toxicity, Da Nang Hospital, Head of the Da Nang Medical Delegation at Bac Giang Hospital, after placing ECMO, the patient improved the blood oxygenation index. However, the prognosis is still severe because of both heart and lung damage. Previously, experts from the Intensive Care Center also booked ECMO for NTT patient, 67 years old, in Bac Giang. The patient tested positive for SARS-CoV-2, then was admitted to Bac Giang Lung Hospital for treatment from June 3 with shortness of breath, cough, SpO2 85%, HFNC breathing and dialysis. According to Dr. Hung, currently, the patient is awake but still dependent on ECMO, the lungs are tending to improve. As of the afternoon of June 15, the Intensive Care Center in Bac Giang is treating 60 patients. In which, 25 patients were successfully weaned from HFNC, 8 patients tested negative for SARS-CoV-2 for the first time and 2 patients tested negative for SARS-CoV-2 for the second time.